This inventor holds 1 USPTO granted patent and 3 published patent applications and 2 EPO patents. Top assignees: Institut Gustave Roussy, Orphelia Pharma. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 101 
1 out of 2 Years Active: 2023
Title: The Innovative Contributions of Mathieu Schmitt
Introduction
Mathieu Schmitt is a notable inventor based in Paris, France. He has made significant contributions to the field of pharmaceuticals, particularly with his innovative work on temozolomide.
Latest Patents
Schmitt holds a patent for an oral suspension of temozolomide. This pharmaceutical liquid suspension comprises temozolomide or a salt thereof, at least one agent controlling the solid state of temozolomide in suspension, a pharmaceutically acceptable liquid vehicle, and optionally at least one acid in a quantity that ensures the pH of the composition is below 5. Additionally, he has developed a powder blend for reconstituting this suspension.
Career Highlights
Throughout his career, Mathieu Schmitt has worked with prominent organizations such as Orphelia Pharma and Institut Gustave Roussy. His experience in these institutions has allowed him to refine his expertise in pharmaceutical innovations.
Collaborations
Schmitt has collaborated with talented individuals in his field, including Maxime Annereau and Jérémy Bastid. These partnerships have contributed to the advancement of his research and development efforts.
Conclusion
Mathieu Schmitt's work in the pharmaceutical industry, particularly his patent for an oral suspension of temozolomide, showcases his innovative spirit and dedication to improving healthcare solutions. His contributions are a testament to the impact of inventors in the field of medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile